|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0034802,
umls-concept:C0036525,
umls-concept:C0449438,
umls-concept:C0871261,
umls-concept:C0879427,
umls-concept:C1522484,
umls-concept:C1527249,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1707520,
umls-concept:C2911692
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-4-2
|
|
pubmed:abstractText |
Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is approved as monotherapy for the treatment of metastatic colorectal cancer. We evaluated the association of tumor EGFR expression levels with outcomes in patients with chemorefractory metastatic colorectal cancer.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2010 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2205-13
|
|
pubmed:meshHeading |
pubmed-meshheading:20332321-Adult,
pubmed-meshheading:20332321-Aged,
pubmed-meshheading:20332321-Aged, 80 and over,
pubmed-meshheading:20332321-Antibodies, Monoclonal,
pubmed-meshheading:20332321-Antineoplastic Agents,
pubmed-meshheading:20332321-Carcinoma,
pubmed-meshheading:20332321-Colorectal Neoplasms,
pubmed-meshheading:20332321-Female,
pubmed-meshheading:20332321-Humans,
pubmed-meshheading:20332321-Male,
pubmed-meshheading:20332321-Middle Aged,
pubmed-meshheading:20332321-Neoplasm Metastasis,
pubmed-meshheading:20332321-Predictive Value of Tests,
pubmed-meshheading:20332321-Prognosis,
pubmed-meshheading:20332321-Receptor, Epidermal Growth Factor,
pubmed-meshheading:20332321-Treatment Outcome,
pubmed-meshheading:20332321-Tumor Markers, Biological,
pubmed-meshheading:20332321-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer.
|
|
pubmed:affiliation |
David Geffen School of Medicine, University of California, Los Angeles, CA 90404, USA. jrhecht@mednet.ucla.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
